UBS Group’s Agios Pharmaceuticals AGIO Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2020
Q2
Sell
-50,000
Closed -$1.77M 7897
2020
Q1
$1.77M Hold
50,000
﹤0.01% 2864
2019
Q4
$2.39M Buy
+50,000
New +$1.89M ﹤0.01% 3379
2017
Q2
Sell
-28,200
Closed -$1.65M 7625
2017
Q1
$1.65M Buy
+28,200
New +$1.35M ﹤0.01% 3117
2016
Q2
Sell
-65,000
Closed -$2.64M 7681
2016
Q1
$2.64M Buy
+65,000
New +$2.78M ﹤0.01% 2419
2015
Q3
Sell
-100
Closed -$11K 8373
2015
Q2
$11K Sell
100
-300
-75% -$32.3K ﹤0.01% 7376
2015
Q1
$38K Sell
400
-100
-20% -$11.2K ﹤0.01% 6296
2014
Q4
$56K Buy
+500
New +$44.6K ﹤0.01% 6349

Other funds holding AGIO

UBS Group's AGIO Position: Q2 2026 in Review

UBS Group increased its Agios Pharmaceuticals (AGIO) stake by 644% in Q2 2026, buying an estimated $25.9M and bringing the position to 985,831 shares worth $36.6M. The position accounts for ﹤0.01% of the portfolio, ranked #2065.

UBS Group first reported a position in AGIO in Q4 2014 and has held it in 47 quarters since. 238 funds tracked by Wall St. Rank hold AGIO as of Q2 2026.

  • UBS Group held 985,831 shares of Agios Pharmaceuticals worth $36.6M as of Q2 2026.
  • UBS Group bought 853,291 Agios Pharmaceuticals shares in Q2 2026, an estimated $25.9M.
  • Agios Pharmaceuticals made up ﹤0.01% of UBS Group's portfolio in Q2 2026, its #2065 holding.
  • UBS Group first reported a position in Agios Pharmaceuticals in Q4 2014 and has held it in 47 quarters since.
  • 238 funds tracked by Wall St. Rank held Agios Pharmaceuticals as of Q2 2026.

Based on UBS Group's 13F filing for Q2 2026, filed 13 Aug 2026.